Astellas Pharma and Immunomic Therapeutics announce worldwide partnership for LAMP-vax™
Immunomic Therapeutics and Astellas Pharma announced an exclusive worldwide license agreement to the LAMP-vax products for treatment or prevention of any and all allergic diseases in humans. Immunomic Therapeutics will receive an upfront payment of $300 million and 10% royalties. October 09, 2015